| Autor: |
Kosiorek HE; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA., Scherber RM; Blueprint Medicines, Cambridge, Massachusetts, USA., Geyer HL; Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA., Verstovsek S; Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA., Langlais BT; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA., Mazza GL; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA., Gotlib J; Stanford University Medical Center, Palo Alto, California, USA., Gupta V; MPN Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Padrnos LJ; Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA., Palmer JM; Department of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA., Fleischman A; Department of Hematology and Oncology, University of California Irvine, Irvine, California, USA., Mesa RA; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, Texas, USA., Dueck AC; Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA. |
Plný text